Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. BOSULIF® (bosutinib) tablets, for oral useBOSULIF® (bosutinib) capsules, for oral use Initial U.S. Approval: 2012
Medication labelWhy this: Advisory · dailymed-prescription
BOSULIF is indicated for the treatment of: •Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies (14.1, 14.2, 14.3)]. •Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2)].
- generic_name
- bosutinib
- product_names
- Bosutinib
- ndc
- 0069-0135, 0069-0136, 0069-0193, 0069-0504, 0069-1014, 0069-0135-01, 0069-0136-01, 0069-0193-01, 0069-0504-30, 0069-1014-15
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en